Ananda Developments PLC Publication of article in Leading Journal

RNS Number : 5105N

Ananda Developments PLC

25 November 2024

 

 25 November 2024

 

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

 

Publication of article about CBD for endometriosis in Leading Journal

 

Ananda Developments plc (AQSE: ANA), a Company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory conditions, is pleased to announce the publication of an article entitled 'Endometriosis: cannabidiol therapy for symptom relief' in Trends in Pharmacological Science (TIPS). TIPS is a monthly peer-reviewed journal and is ranked in the top 2% of scientific journals worldwide.

'Endometriosis: cannabidiol therapy for symptom relief', authored by Dr Lucy Whitaker and Professors Andrew Horne and Philippa Saunders of the University of Edinburgh and Professor Clive Page and Charles Morgan of Ananda, highlights that cannabidiol (CBD) is a promising therapeutic agent for endometriosis because it has analgesic, anti-inflammatory, immunomodulatory, anti-angiogenic, antiproliferative, and neuroprotective effects. It summarises data from patient samples and animal models focussed on the pathophysiology of endometriosis, including pathways where CBD has activity, and considers the available formulations of CBD-containing products, their pharmacokinetics (PK), and their use in ongoing clinical trials in endometriosis and other pain conditions.

Charles Morgan, Chairman, said: 'The potential of CBD as a safe, efficacious and cost-effective treatment for the symptoms of endometriosis is compelling, and we are encouraged by this recognition in the publication of this review of the data in such a prestigious journal as Trends in Pharmacological Science. We look forward to working with investigators at the University of Edinburgh as they test this hypothesis in the upcoming ENDOCAN clinical trial.

Our involvement with this research is part of Ananda's commitment to developing a licensed CBD-based medicine, available on the NHS, for the treatment of the symptoms of endometriosis, a condition which affects 10% of women globally.'

The article can be accessed here: https://investors.anandadevelopments.com/s/00e2d1

-Ends-

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

  

-Ends-  

  

The Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA DEVELOPMENTS PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	[phone]
Corporate Finance
Richard Morrison
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

 

 

About Ananda Developments  

  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

   

https://investors.anandadevelopments.com/link/4PKM7e

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABABLTMTITMTI